The New England Journal of Medicine April 14, 2022

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Jennifer Hammond, Heidi Leister-Tebbe, Annie Gardner, et al.

Bottom Line

In unvaccinated, nonhospitalized adults with mild-to-moderate COVID-19 and high risk for severe disease, early treatment with nirmatrelvir plus ritonavir (Paxlovid) reduced the risk of hospitalization or death by 89% compared to placebo.

Key Findings

1. In the interim analysis of patients treated within 3 days of symptom onset, the incidence of COVID-19-related hospitalization or death by day 28 was 0.77% (3 of 389 patients) in the nirmatrelvir group versus 7.01% (27 of 385 patients) in the placebo group, representing an 89.1% relative risk reduction (P<0.001) [2.2.1].

2. In the final modified intention-to-treat analysis of patients treated within 5 days of symptom onset (N=2,085), the incidence of hospitalization or death was 0.77% (8 of 1,039) in the nirmatrelvir group compared to 6.31% (66 of 1,046) in the placebo group.

3. Across the entire study population, there were 0 deaths in the nirmatrelvir group and 13 deaths in the placebo group through day 28.

4. The incidence of adverse events emerging during the treatment period was similar between groups (22.6% with nirmatrelvir-ritonavir vs. 23.9% with placebo); dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) were more common with the active drug.

Study Design

Design

RCT

Double-Blind

Sample

2,246

Patients

Duration

28 days

Median

Setting

Multinational

Population Unvaccinated, nonhospitalized adults (≥18 years) with confirmed SARS-CoV-2 infection, mild-to-moderate symptoms with onset within 5 days, and at least one risk factor for progression to severe disease.

Intervention Nirmatrelvir 300 mg plus ritonavir 100 mg administered orally every 12 hours for 5 days.

Comparator Matching placebo administered orally every 12 hours for 5 days.

Outcome Covid-19-related hospitalization or death from any cause through day 28.

Study Limitations

• The trial exclusively enrolled unvaccinated adults, limiting its immediate definitive generalizability to highly vaccinated populations with hybrid immunity.

• The study was conducted primarily during the Delta variant wave, meaning primary efficacy data did not natively evaluate outcomes against Omicron and its subsequent sublineages.

• Ritonavir is a potent CYP3A4 inhibitor, creating significant and sometimes absolute contraindications for patients taking certain common concomitant medications (e.g., statins, direct oral anticoagulants, calcineurin inhibitors).

• The trial did not actively evaluate or quantify 'COVID-19 rebound' (a return of symptoms or viral load after completing the 5-day course), a phenomenon that was later recognized in clinical practice.

Clinical Significance

EPIC-HR established nirmatrelvir-ritonavir (Paxlovid) as the highly effective, first-line oral antiviral therapy for preventing severe COVID-19 in high-risk outpatients. By achieving an 89% relative risk reduction in hospitalization or death, its efficacy rivaled that of intravenous monoclonal antibodies while offering the logistical advantage of oral administration. This profoundly altered the management of outpatient COVID-19, dramatically reducing the burden on healthcare systems, provided prescribers carefully navigated complex drug-drug interactions.

Historical Context

Published in early 2022, EPIC-HR was conducted in 2021 before the Omicron variant became globally dominant and before vaccines had reached all high-risk populations worldwide. Prior to Paxlovid, outpatient treatment options for COVID-19 were largely limited to intravenous monoclonal antibodies (which were logistically difficult to administer and frequently lost efficacy as the virus mutated) and molnupiravir (which demonstrated a comparatively modest ~30% risk reduction and carried mutagenesis concerns). The advent of a highly potent, orally bioavailable protease inhibitor marked a major turning point in the transition from an unmanageable pandemic to a treatable endemic disease.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the mechanistic rationale for co-administering ritonavir with nirmatrelvir in the treatment of COVID-19, and what pharmacokinetic principle does this illustrate?

Key Response

Nirmatrelvir is a SARS-CoV-2 main protease (Mpro) inhibitor. Ritonavir has no direct activity against SARS-CoV-2 but is a potent CYP3A4 inhibitor. It acts as a pharmacokinetic enhancer (booster) to slow the hepatic metabolism of nirmatrelvir, maintaining its plasma concentrations in the therapeutic range.

Resident

When prescribing nirmatrelvir-ritonavir to a high-risk outpatient, what major physiological and pharmacological parameters must be evaluated before initiation?

Key Response

Clinicians must assess renal function (dose adjustment is required for eGFR 30-59 mL/min, and it is contraindicated if <30) and hepatic impairment. Crucially, due to ritonavir's potent CYP3A4 inhibition, a rigorous medication reconciliation must be performed to avoid life-threatening drug-drug interactions (e.g., with statins, DOACs, or immunosuppressants).

Fellow

The EPIC-HR trial exclusively enrolled unvaccinated patients. How do subsequent data from trials like EPIC-SR and observational cohorts inform the utility of nirmatrelvir-ritonavir in vaccinated populations or those with hybrid immunity?

Key Response

While EPIC-HR demonstrated an 89% relative risk reduction in severe outcomes for unvaccinated, naive patients, subsequent data in highly vaccinated or seropositive populations (like the EPIC-SR trial) showed an attenuated absolute risk reduction. Fellows must synthesize this to weigh the risk-benefit and cost-effectiveness of prescribing the drug to standard-risk vaccinated patients.

Attending

Given the post-market phenomenon of 'Paxlovid rebound', how should you counsel high-risk patients regarding the clinical significance, risk of severe disease, and transmissibility upon symptom recurrence?

Key Response

Attendings must emphasize that while rebound (recurrent symptoms or viral load after completing therapy) can occur, it does not typically represent treatment failure, viral resistance, or a risk for severe progression. However, patients must be counseled to reinstitute isolation precautions during a rebound to prevent transmission.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The EPIC-HR trial was stopped early due to overwhelming efficacy. What are the statistical risks of truncating a randomized controlled trial early for benefit, particularly regarding the estimation of treatment effect size and the detection of rare safety signals?

Key Response

Stopping a trial early for benefit can lead to an overestimation of the treatment effect size (often capturing a 'random high' in the data) and inherently limits the accumulation of safety data. For a novel drug deployed globally, this limits the statistical power to detect rare but serious adverse events or long-term complications.

Journal Editor

As a peer reviewer evaluating the EPIC-HR manuscript, what critical limitations regarding the study's external validity in the context of viral evolution would you flag for the authors to address?

Key Response

A critical threat to external validity is that the trial was conducted during the Delta wave in a population without prior infection or vaccination. An editor would require the authors to explicitly state how viral evolution (e.g., the emergence of Omicron) and widespread population immunity might alter the drug's absolute efficacy and applicability in future waves.

Guideline Committee

Based on the EPIC-HR trial, how do current NIH and IDSA guidelines position nirmatrelvir-ritonavir for nonhospitalized high-risk adults, and what specific clinical scenarios necessitate caution or alternative therapies according to these guidelines?

Key Response

The NIH COVID-19 Treatment Guidelines strongly recommend nirmatrelvir-ritonavir as the preferred first-line therapy for high-risk nonhospitalized adults. However, guidelines explicitly advise alternative therapies (like remdesivir or molnupiravir) when significant, unmanageable drug-drug interactions exist or when patients have severe renal impairment (eGFR <30), directly reflecting the pharmacological limitations noted in EPIC-HR.

Clinical Landscape

Noteworthy Related Trials

2021

MOVe-OUT Trial

n = 1,433 · NEJM

Tested

Molnupiravir 800mg twice daily for 5 days

Population

Nonhospitalized adults with mild-to-moderate Covid-19 at high risk for progression

Comparator

Placebo

Endpoint

Hospitalization or death through day 29

Key result: Molnupiravir significantly reduced the risk of hospitalization or death by approximately 30 percent compared to placebo.

2021

PINETREE Trial

n = 562 · NEJM

Tested

Intravenous remdesivir for 3 days

Population

Nonhospitalized patients with Covid-19 at high risk for disease progression

Comparator

Placebo

Endpoint

Covid-19-related hospitalization or death from any cause by day 28

Key result: A 3-day course of intravenous remdesivir resulted in an 87 percent lower risk of hospitalization or death than placebo.

2021

COMET-ICE Trial

n = 1,057 · NEJM

Tested

Sotrovimab 500mg single intravenous infusion

Population

High-risk, nonhospitalized adults with mild-to-moderate Covid-19

Comparator

Placebo

Endpoint

Hospitalization or death from any cause by day 29

Key result: Sotrovimab reduced the risk of disease progression leading to hospitalization or death by 85 percent.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis